Sanofi: more investments for cemiplimab antibody

(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals Inc.
announced on Monday their intensification and increased investment in the clinical development of the cemiplimab anti-PD-1 (programmed cell death receptor-1) antibody in oncology, as well as the dupilumab antibody in the treatment of type 2 allergic diseases.

Both these innovative therapies will potentially benefit many different patient populations and these strategic investments will enable both companies to assess cemiplimab and dupilumab as part of large-scale clinical development programs.

By virtue of this decision, Sanofi and Regeneron will increase their investments in the clinical development of cemiplimab to 1.64 billion dollars, which is about 1 billion dollars more than what was included in the initial 2015 agreement, which they will continue to finance equally.


Copyright (c) 2018 CercleFinance.com. All rights reserved.